<DOC>
	<DOCNO>NCT00862251</DOCNO>
	<brief_summary>The purpose study determine efficacy switch combination tablet ezetimibe/simvastatin ( 10mg/20mg ) versus rosuvastatin ( 10 mg ) versus double statin dose patient cardiovascular disease diabetes mellitus adequately control simvastatin 20 mg atorvastatin 10 mg .</brief_summary>
	<brief_title>Ezetimibe/Simvastatin ( MK-0653A ) Versus Rosuvastatin Versus Doubling Statin Dose Participants With Cardiovascular Disease Diabetes Mellitus ( MK-0653A-133 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Patient take common statin ezetimibe within 6 week study screen patient currently take daily dose follow statin 6 week prior study screen : simvastatin , atorvastatin , pravastatin , fluvastatin , ezetimibe , lovastatin , ezetimibe + fluvastatin Patient willing go cholesterol glucose lower diet duration study Patient willing remain abstinent use birth control duration study Patient Diabetes Mellitus cardiovascular disease Patient sensitivity certain common statin drug Patient Asian would able start take high dos rosuvastatin necessary study design Patient consume 2 alcoholic drink per day Patient pregnant breastfeeding Patient treat investigational drug within 30 day first visit Patient currently prohibit dos follow statin drug : rosuvastatin , simvastatin , atorvastatin , pravastatin Patient congestive heart failure Patient uncontrolled high blood pressure Patient kidney disease Patient uncontrolled endocrine metabolic disease know possibly increase blood lipoprotein Patient diabetes mellitus well control Patient human immunodeficiency virus ( HIV ) positive Patient currently take medication inhibit Cytochrome P450 3A4 ( CYP3A4 ) Patient currently take therapy would increase risk muscle weakness Patient take certain thecounter lipidlowering agent within 6 week prior visit 1 Patient currently take psyllium fiberbased laxative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>cardiovascular disorder</keyword>
</DOC>